**3.10 Cost-effectiveness**

Some of the clinical trials have covered heath economic analyses up to twelve months after surgery. All these studies find OPCAB to be less costly while providing a similar gain of Quality Adjusted Life Years (12-13, 24, 29, 50). As an example, the Octopus study (24) found costs of OPCAB to be \$13.069 versus \$14.908 (P<0,01) at one year follow up for a one year QALY of 0,83 in the CCABG group versus 0,82 in the OPCAB group. Long term data on health economics are not available.
